Glucopar-VD 100 SR Tablet contains Vildagliptin 100 mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Vildagliptin works by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner, which helps improve glycemic control without causing significant hypoglycemia. This sustained-release formulation ensures a steady plasma concentration, promoting better compliance and consistent therapeutic effects. Glucopar-VD 100 SR is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin when diet and exercise alone are insufficient to achieve target blood glucose levels. The medication is generally well-tolerated; however, patients should be monitored for potential adverse effects including headache, dizziness, gastrointestinal disturbances, and rare instances of pancreatitis. Renal function should be assessed prior to initiation and periodically during treatment, as dosage adjustments may be necessary in patients with renal impairment. Glucopar-VD 100 SR Tablet should be used under medical supervision, with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes and minimize complications associated with diabetes.